{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:31:01Z","timestamp":1769603461712,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00280-018-3742-1","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T16:21:06Z","timestamp":1543681266000},"page":"431-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose-dense paclitaxel\/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-4197","authenticated-orcid":false,"given":"Gabriella","family":"Ferrandina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-6146","authenticated-orcid":false,"given":"Giacomo","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1884-723X","authenticated-orcid":false,"given":"Giuseppe","family":"Vitrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-9379","authenticated-orcid":false,"given":"Valerio","family":"Gallotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9026-2554","authenticated-orcid":false,"given":"Eleonora","family":"Palluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-702X","authenticated-orcid":false,"given":"Mariagrazia","family":"Distefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"3742_CR1","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/jnci\/91.6.500a","volume":"91","author":"C McNeil","year":"1999","unstructured":"McNeil C (1999) New standard of care for cervical cancer sets stage for next questions. J Natl Cancer Inst 91:500\u2013501","journal-title":"J Natl Cancer Inst"},{"key":"3742_CR2","first-page":"CD008285","volume":"1","author":"C","year":"2010","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC) (2010) Reducing uncertainties about the effect of chemoradiotherapy for cervical cancer: individual patients data meta-analysis. Cochrane Database Syst Rev 1:CD008285","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3742_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/jamaoncol.2017.5179","volume":"4","author":"S Shrivastava","year":"2018","unstructured":"Shrivastava S, Mahantshetty U, Engineer R, Gynecologic Disease Management Group et al (2018) Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol 4(4):506\u2013513","journal-title":"JAMA Oncol"},{"issue":"1","key":"3742_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/JCO.2002.20.1.179","volume":"20","author":"P Benedetti-Panici","year":"2002","unstructured":"Benedetti-Panici P, Greggi S, Colombo A et al (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20(1):179\u2013188","journal-title":"J Clin Oncol"},{"key":"3742_CR5","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/S0959-8049(03)00425-8","volume":"39","author":"Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39:2470\u20132486","journal-title":"Eur J Cancer"},{"issue":"18","key":"3742_CR6","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1200\/JCO.2005.04.172","volume":"23","author":"A Buda","year":"2005","unstructured":"Buda A, Fossati R, Colombo N et al (2005) Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, fosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 23(18):4137\u20134145","journal-title":"J Clin Oncol"},{"issue":"4","key":"3742_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/annonc\/mdn690","volume":"20","author":"AA Lissoni","year":"2009","unstructured":"Lissoni AA, Colombo N, Pellegrino A et al (2009) A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 20(4):660\u2013665","journal-title":"Ann Oncol"},{"issue":"9","key":"3742_CR8","first-page":"14693","volume":"8","author":"D He","year":"2015","unstructured":"He D, Duan C, Chen J et al (2015) The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer: a systematic review and meta analysis. Int J Clin Exp Med 8(9):14693\u201314700","journal-title":"Int J Clin Exp Med"},{"key":"3742_CR9","first-page":"CD010260","volume":"4","author":"F Kokka","year":"2015","unstructured":"Kokka F, Bryant A, Brockbank E et al (2015) Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 4:CD010260","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"3742_CR10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","volume":"36","author":"S Gupta","year":"2018","unstructured":"Gupta S, Maheshwari A, Parab P et al (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1548\u20131555","journal-title":"J Clin Oncol"},{"issue":"28","key":"3742_CR11","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","volume":"27","author":"BJ Monk","year":"2009","unstructured":"Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27(28):4649\u20134655","journal-title":"J Clin Oncol"},{"issue":"19","key":"3742_CR12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III Trial JCOG0505. J Clin Oncol 33(19):2129\u20132135","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"3742_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","volume":"6","author":"L Norton","year":"2001","unstructured":"Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6(Suppl 3):30\u201335","journal-title":"Oncologist"},{"key":"3742_CR14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642\u20131649","journal-title":"J Clin Oncol"},{"key":"3742_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djq409","volume":"102","author":"L Bonilla","year":"2010","unstructured":"Bonilla L, Ben-Aharon I, Vidal L et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845\u20131854","journal-title":"J Natl Cancer Inst"},{"issue":"9698","key":"3742_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331\u20131338","journal-title":"Lancet"},{"issue":"4","key":"3742_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/IGC.0b013e3181d80aa9","volume":"20","author":"T Mori","year":"2010","unstructured":"Mori T, Hosokawa K, Sawada M et al (2010) Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results. Int J Gynecol Cancer 20(4):611\u2013616","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3742_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000381461","volume":"89","author":"P Benedetti Panici","year":"2015","unstructured":"Benedetti Panici P, Palaia I, Marchetti C et al (2015) Dose-dense neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer: a phase II study. Oncology 89(2):103\u2013110","journal-title":"Oncology"},{"issue":"2","key":"3742_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ygyno.2015.05.042","volume":"138","author":"I Vergote","year":"2015","unstructured":"Vergote I, Debruyne P, Kridelka F et al (2015) Phase II study of weekly paclitaxel\/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: a study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecol Oncol 138(2):278\u2013284","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3742_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ejca.2012.10.008","volume":"49","author":"F Zanaboni","year":"2013","unstructured":"Zanaboni F, Grijuela B, Giudici S et al (2013) Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II multicentric study. Eur J Cancer 49(5):1065\u20131072","journal-title":"Eur J Cancer"},{"issue":"6","key":"3742_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/IGC.0000000000001021","volume":"27","author":"R Salihi","year":"2017","unstructured":"Salihi R, Leunen K, Moerman P et al (2017) Neoadjuvant weekly paclitaxel-carboplatin is effective in Stage I\u2013II cervical cancer. Int J Gynecol Cancer 27(6):1256\u20131260","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"3742_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12032-017-0992-4","volume":"34","author":"M Tanioka","year":"2017","unstructured":"Tanioka M, Yamaguchi S, Shimada M et al (2017) Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. Med Oncol 34(8):134","journal-title":"Med Oncol"},{"issue":"3","key":"3742_CR23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.21873\/anticanres.11441","volume":"37","author":"A Gadducci","year":"2017","unstructured":"Gadducci A, Barsotti C, Laliscia C et al (2017) Dose-dense paclitaxel- and carboplatin-based neoadjuvant chemotherapy followed by surgery or concurrent chemo-radiotherapy in cervical cancer: a preliminary analysis. Anticancer Res 37(3):1249\u20131255","journal-title":"Anticancer Res"},{"issue":"9","key":"3742_CR24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ejca.2012.01.006","volume":"48","author":"S Torfs","year":"2012","unstructured":"Torfs S, Cadron I, Amant F et al (2012) Evaluation of paclitaxel\/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. Eur J Cancer 48(9):1332\u20131340","journal-title":"Eur J Cancer"},{"issue":"12","key":"3742_CR25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/bjc.2013.230","volume":"108","author":"M McCormack","year":"2013","unstructured":"McCormack M, Kadalayil L, Hackshaw A et al (2013) A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 108(12):2464\u20132469","journal-title":"Br J Cancer"},{"issue":"3","key":"3742_CR26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2017.07.006","volume":"146","author":"CRAS Azevedo de","year":"2017","unstructured":"de Azevedo CRAS, Thuler LCS, de Mello MJG et al (2017) Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol 146(3):560\u2013565","journal-title":"Gynecol Oncol"},{"issue":"7","key":"3742_CR27","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.ejso.2018.04.019","volume":"44","author":"G Ferrandina","year":"2018","unstructured":"Ferrandina G, Palluzzi E, Gallotta V et al (2018) Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: a phase II study. Eur J Surg Oncol 44(7):1062\u20131068","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"3742_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3742_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ygyno.2009.07.027","volume":"115","author":"D Querleu","year":"2009","unstructured":"Querleu D, Morrow CP (2009) Classification of radical hysterectomy. Gynecol Oncol 115(2):314\u2013315","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3742_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0167-8140(93)90260-F","volume":"26","author":"D Chassagne","year":"1993","unstructured":"Chassagne D, Sismondi P, Horiot JC et al (1993) A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 26(3):195\u2013202","journal-title":"Radiother Oncol"},{"issue":"1","key":"3742_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310","journal-title":"Control Clin Trials"},{"key":"3742_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"FL Kaplan","year":"1958","unstructured":"Kaplan FL, Meier P (1958) Non parametric estimation from incomplete observations. Am J Stat Assoc 53:457\u2013481","journal-title":"Am J Stat Assoc"},{"key":"3742_CR33","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163\u2013170","journal-title":"Cancer Chemother Rep"},{"issue":"suppl_5","key":"3742_CR34","doi-asserted-by":"publisher","first-page":"v605","DOI":"10.1093\/annonc\/mdx440.039","volume":"28","author":"AR Clamp","year":"2017","unstructured":"Clamp AR, McNeish I, Dean A et al (2017) ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian\/fallopian tube\/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Ann Oncol 28(suppl_5):v605\u2013v649","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3742-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3742-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3742-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T08:05:18Z","timestamp":1575273918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3742-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3742"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3742-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]},"assertion":[{"value":"1 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest. The authors are responsible for the content and writing of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}